Pharmaceutical Executive Europe - November/December 2007 - (Page 3)
Pharmaceutical Executive Europe Nov/Dec 2007 Contents 3 Pharmaceutical Executive Advancing business leadership www.pharmexeceurope.com Special Report A Year in Pharma Sarah Houlton As 2007 draws to a close, Sarah Houlton examines the lasting impact of this year’s major acquisitions, approvals and partnerships, and speculates on what surprises 2008 may have in store for the global pharma industry. page 18 Health Economics Working With IQWiG Frank-Ulrich Fricke Over the last two years, the introduction of new costcontainment measures has seen the German healthcare landscape change dramatically. As the role of IQWiG evolves, how do companies adapt to work within this new structure? page 24 World Health Developing Strategies for Developing Countries Anne V. Reeler and Joseph Saba The HIV/AIDS epidemic in the developing world has altered the assumption that drugs must be priced identically in separate markets. With compulsory licensing and parallel imports challenging the TRIPS agreement, just how low can pharma prices go? page 28 Risk Management Due Pharmacovigilance Gadi Saarony Its products are a pharmaceutical company’s most important and valuable assets. Treating pharmacovigilance as an aspect of good investment practice may be the key to optimizing portfolio value by balancing risk and potential return. page 32
http://www.pharmexeceurope.com
Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - November/December 2007